Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report)’s stock price was down 3.2% on Thursday .The company traded as low as $20.33 and last traded at $20.46. Approximately 9,646 shares ...

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025On track to initiate a proof-of-concept study in ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended ...

Oruka Therapeutics (ORKA) announced that it is expected to be added to the Nasdaq Biotechnology Index (NBI). Oruka’s addition will become effective prior to market open on Monday, December 23rd ...

Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of ...

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life ...

Oruka Therapeutics, Inc. MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to ...

Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment ...